Defending Against Claims Alleging Allergic Hypersensitivity
Live · 2 CLE credits · November 18, 2026, 2:30 PM ET
An allergic reaction is not a defect. Learn to attack causation with dose, route, and threshold-dose science, deploy Rule 12 and preemption motions, challenge plaintiffs' experts under Rule 702, and carry a science-driven defense theme through trial.
An allergic reaction is not a product defect — and the whole case turns on whether you can prove it
Allergic hypersensitivity claims — contact, respiratory, food, and drug — are being reshaped by recent law. The 2023 amendments to Rule 702 sharpened judicial gatekeeping, and the Supreme Court's 2026 decision in Monsanto v. Durnell extended labeling preemption from medical devices to EPA-registered products.
The stakes are already concrete. Plead without product-specific facts, and Twiqbal ends the case at Rule 12. Miss the sensitizer-versus-irritant distinction, and the causation record unravels. Skip a threshold-dose assessment, and In re Zantac says the claim should not survive. Overlook Riegel and Durnell, and a preemption defense goes unused.
Attendees leave with phase-by-phase practice pointers from intake to verdict: analyzing the complaint, Rule 12 and preemption motions, discovery aimed at dose and route, deposing and crossing plaintiffs' experts, Rule 702 and summary judgment briefing, and science-grounded defense themes built for a jury.
Key topics
- Science of Sensitization: How the four hypersensitivity classifications, the sensitizer-versus-irritant distinction, and diagnostic tools — patch, skin-prick, IgE, and oral challenge testing — shape what a litigator must prove or refute.
- Dose, Route, Threshold: Why dose "makes the poison" in the courtroom: exposure and route analysis, threshold dose under In re Zantac, ADME, and biomarkers as evidence of causation.
- Claims and Defenses: How strict liability, negligence, failure to warn, design defect, and "hypoallergenic" consumer protection claims fare when the reaction is idiosyncratic — and the affirmative defenses that answer them.
- Rule 12 and Preemption: How Twiqbal plausibility attacks, judicial notice of FDA materials, the learned intermediary doctrine, and preemption after Riegel and Monsanto v. Durnell can end a case before discovery.
- General vs. Specific Causation: How epidemiology, dose-response, background risk, the Bradford Hill criteria, differential diagnosis, latency, and Rule 35 genetic testing decide whether a hypersensitivity claim survives.
- Daubert Through Trial: How to challenge expert testimony under amended Rule 702, win summary judgment, and carry a science-grounded defense theme through jury presentation, cross-examination, and closing argument.
Agenda
- Why Allergic Hypersensitivity Cases Are Different: The Science a Litigator Needs, Claims, and Motions Practice
- Causation, Rule 702 / Daubert Challenges, Summary Judgment, and Trial Strategy
Faculty
- Grant W. Hollingsworth, Hollingsworth LLP
- Joseph F. Altieri, Hollingsworth LLP
State accreditation
- AK: Approved for CLE Credits, 2 General
- AL: Approved for CLE Credits, 2 General
- AR: Approved for CLE Credits, 2 General
- AZ: Approved for CLE Credits, 2 General
- CA: Approved for CLE Credits, 2 General
- CO: Pending CLE Approval, 2 General
- CT: Approved for CLE Credits, 2 General
- DC: No MCLE Required, 2 CLE Hour(s)
- DE: Pending CLE Approval, 2 General
- FL: Approved via Attorney Submission, 2 General Hours
- GA: Approved for CLE Credits, 2 General
- HI: Approved for CLE Credits, 2 General
- IA: Pending CLE Approval, 2 General
- ID: Pending CLE Approval, 2 General
- IL: Approved for CLE Credits, 2 General
- IN: Approved for CLE Credits, 2 General
- KS: Pending CLE Approval, 2 Substantive
- KY: Pending CLE Approval, 2 General
- LA: Pending CLE Approval, 2 General
- MA: No MCLE Required, 2 CLE Hour(s)
- MD: No MCLE Required, 2 CLE Hour(s)
- ME: Pending CLE Approval, 2 General
- MI: No MCLE Required, 2 CLE Hour(s)
- MN: Pending CLE Approval, 2 General
- MO: Approved for CLE Credits, 2.4 General
- MS: Pending CLE Approval, 2 General
- MT: Pending CLE Approval, 2 General
- NC: Pending CLE Approval, 2 General
- ND: Approved for CLE Credits, 2 General
- NE: Pending CLE Approval, 2 General
- NH: Approved for CLE Credits, 120 General minutes
- NJ: Approved for CLE Credits, 2 General
- NM: Approved for CLE Credits, 2 General
- NV: Approved for CLE Credits, 2 General
- NY: Approved for CLE Credits, 2 General
- OH: Approved for CLE Credits, 2 General
- OK: Pending CLE Approval, 2.5 General
- OR: Pending CLE Approval, 2 General
- PA: Approved for CLE Credits, 2 General
- RI: Pending CLE Approval, 2.5 General
- SC: Pending CLE Approval, 2 General
- SD: No MCLE Required, 2 CLE Hour(s)
- TN: Approved for CLE Credits, 2 General
- TX: Approved for CLE Credits, 2 General
- UT: Pending CLE Approval, 2 General
- VA: Not Eligible, 2 General Hours
- VT: Approved for CLE Credits, 2 General
- WA: Approved via Attorney Submission, 2 Law & Legal Hours
- WI: Approved for CLE Credits, 2 General
- WV: Pending CLE Approval, 2.4 General
- WY: Pending CLE Approval, 2 General